PharmaDepth

Company profile

AQUESTIVE THERAPEUTICS, INC.

NASDAQ:AQSTBiotechnology: Pharmaceutical Preparations

Drug pipeline (5)

AssetStageRevenueTrialsStatus
EXSERVANapproved—3approved
LIBERVANTapproved—4approved
ZUPLENZapproved—6approved
ONDANSETRONphase1—6no active trials
RILUZOLEphase1—3completed, terminated, withdrawn

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (9)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT07703982phase1completed2024-12-262025-03-14Aquestive TherapeuticsA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of DESF in Pediatric Subjects
NCT03953820phase1_2completed2019-04-132019-07-31Aquestive TherapeuticsDiazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study
NCT06527937phase2completed2024-07-172024-10-10Aquestive TherapeuticsPharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome
NCT03222349phase2completed2017-08-312020-01-28Aquestive TherapeuticsPharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
NCT03679975phase2terminated2018-04-042018-09-26Aquestive TherapeuticsRiluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

FDA applications (4)

ApplicationApprovedTypeApplicantProducts
NDA 2126402019-11-22NDAAQUESTIVE THERAPEUTICS INC
NDA 0225242010-07-02NDAAQUESTIVE THERAPEUTICS INC
NDA 212641—NDAAQUESTIVE
NDA 218623—NDAAQUESTIVE